drugset / Trial / NCT03795779
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Phase 0
Unknown
20 enrolled
iCell Gene Therapeutics
Peking University Shenzhen Hospital · collabThe General Hospital of Western Theater Command · collabiCAR Bio Therapeutics Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CLL1-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.
Timeline
- Start
- 2018-03-01
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLL1-CD33 cCAR T cells | Cell therapy | — | — |